Literature DB >> 15172440

Cytomegalovirus infection after bone marrow transplantation in children.

Elio Castagnola1, Barbara Cappelli, Daniela Erba, Anna Rabagliati, Edoardo Lanino, Giorgio Dini.   

Abstract

Cytomegalovirus (CMV) is a well-known cause of disease occurring after bone marrow transplantation (BMT). The manifestations of CMV range from asymptomatic infection, defined as active CMV replication in the blood in the absence of clinical manifestations or organ failure abnormalities, to CMV disease, characterized by CMV infection with clinical symptoms or organ function abnormalities. Diagnostic procedures to assess the viral load have improved greatly with the increased use of antigenemia, CMV DNA, and immediate early-messenger RNA. Many conditions concur in determining the risk of developing CMV reactivation or disease after bone marrow transplant with serologic status of donor and recipient, type of bone marrow transplant, presence of graft-versus-host disease being the most studied. However, time and quality of immune reconstitution seems to be the pivotal factors. Pneumonia and gastrointestinal involvement are the most frequently documented clinical pictures with late-onset CMV reactivation or disease representing a new challenge. CMV prophylaxis or pre-emptive therapy adopted during the last few years in allogeneic BMT recipients has changed the natural history of the disease, reducing the risk of CMV disease, CMV-associated death, transplant-related mortality, and has prolonged the period at risk. Specific studies on children are lacking, however, the clinical pictures and features seems to be similar both in children and adults.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172440     DOI: 10.1016/j.humimm.2004.02.013

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  17 in total

1.  Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.

Authors:  Malaya K Sahoo; Martina I Lefterova; Fumiko Yamamoto; Jesse J Waggoner; Sunwen Chou; Susan P Holmes; Matthew W Anderson; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

2.  Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection.

Authors:  Katja C Erlach; Verena Böhm; Christof K Seckert; Matthias J Reddehase; Jürgen Podlech
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples.

Authors:  Joseph D Tario; George L Chen; Theresa E Hahn; Dalin Pan; Rosemary L Furlage; Yali Zhang; Liselotte Brix; Charlotte Halgreen; Kivin Jacobsen; Philip L McCarthy; Paul K Wallace
Journal:  Cytometry B Clin Cytom       Date:  2014-10-23       Impact factor: 3.058

4.  Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons.

Authors:  Giovanni Almanzar; Susanne Schwaiger; Brigitte Jenewein; Michael Keller; Dietmar Herndler-Brandstetter; Reinhard Würzner; Diether Schönitzer; Beatrix Grubeck-Loebenstein
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus.

Authors:  Seung Beom Han; E Young Bae; Jae Wook Lee; Pil Sang Jang; Dong-Gun Lee; Nack-Gyun Chung; Dae Chul Jeong; Bin Cho; Soon Ju Lee; Jin Han Kang; Hack-Ki Kim
Journal:  Int J Hematol       Date:  2014-07-01       Impact factor: 2.490

6.  Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model.

Authors:  M Shane Smith; Devorah C Goldman; Alexis S Bailey; Dana L Pfaffle; Craig N Kreklywich; Doran B Spencer; Florence A Othieno; Daniel N Streblow; J Victor Garcia; William H Fleming; Jay A Nelson
Journal:  Cell Host Microbe       Date:  2010-09-16       Impact factor: 21.023

7.  Increased morbidity and mortality in murine cytomegalovirus-infected mice following allogeneic bone marrow transplant is associated with reduced surface decay accelerating factor expression.

Authors:  I S El-Amouri; M Bani-Ahmad; Y Tang-Feldman; F Lin; C Ko; C Pomeroy; O R Oakley
Journal:  Clin Exp Immunol       Date:  2010-09-14       Impact factor: 4.330

8.  Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status.

Authors:  Raphael Carapito; Ismail Aouadi; Angélique Pichot; Perrine Spinnhirny; Aurore Morlon; Irina Kotova; Cécile Macquin; Véronique Rolli; Anne Cesbron; Katia Gagne; Machteld Oudshoorn; Bronno van der Holt; Myriam Labalette; Eric Spierings; Christophe Picard; Pascale Loiseau; Ryad Tamouza; Antoine Toubert; Anne Parissiadis; Valérie Dubois; Catherine Paillard; Myriam Maumy-Bertrand; Frédéric Bertrand; Peter A von dem Borne; Jürgen H E Kuball; Mauricette Michallet; Bruno Lioure; Régis Peffault de Latour; Didier Blaise; Jan J Cornelissen; Ibrahim Yakoub-Agha; Frans Claas; Philippe Moreau; Dominique Charron; Mohamad Mohty; Yasuo Morishima; Gérard Socié; Seiamak Bahram
Journal:  Bone Marrow Transplant       Date:  2020-04-14       Impact factor: 5.483

9.  Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.

Authors:  Jill C Beck; John E Wagner; Todd E DeFor; Claudio G Brunstein; Mark R Schleiss; Jo-Anne Young; Daniel H Weisdorf; Sarah Cooley; Jeffrey S Miller; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-26       Impact factor: 5.742

10.  Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT.

Authors:  T Bontant; P Sedlaçek; A Balduzzi; B Gaspar; S Cesaro; H Einsele; C Peters; J-H Dalle
Journal:  Bone Marrow Transplant       Date:  2013-10-28       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.